2,584 Shares in Danaher Corporation $DHR Acquired by Camelot Portfolios LLC

Camelot Portfolios LLC bought a new stake in Danaher Corporation (NYSE:DHR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,584 shares of the conglomerate’s stock, valued at approximately $492,000.

Several other hedge funds also recently bought and sold shares of the stock. Headlands Technologies LLC raised its holdings in shares of Danaher by 90.5% in the second quarter. Headlands Technologies LLC now owns 2,440 shares of the conglomerate’s stock worth $465,000 after acquiring an additional 1,159 shares during the last quarter. Moore Capital Management LP acquired a new stake in shares of Danaher during the second quarter valued at $3,224,000. Two Sigma Securities LLC purchased a new stake in Danaher during the 2nd quarter worth about $778,000. Benjamin Edwards Inc. increased its position in Danaher by 43.2% during the 2nd quarter. Benjamin Edwards Inc. now owns 19,960 shares of the conglomerate’s stock worth $3,802,000 after purchasing an additional 6,026 shares in the last quarter. Finally, Flputnam Investment Management Co. raised its stake in Danaher by 4.2% in the 2nd quarter. Flputnam Investment Management Co. now owns 14,389 shares of the conglomerate’s stock valued at $2,741,000 after purchasing an additional 584 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DHR. Evercore reaffirmed an “outperform” rating and set a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. DZ Bank initiated coverage on shares of Danaher in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price objective for the company. Stifel Nicolaus decreased their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Wolfe Research cut shares of Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Finally, Guggenheim cut their price target on Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Stock Up 0.2%

DHR opened at $216.41 on Monday. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The business has a 50-day moving average of $199.46 and a two-hundred day moving average of $192.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a market capitalization of $152.13 billion, a price-to-earnings ratio of 38.44, a price-to-earnings-growth ratio of 2.69 and a beta of 0.78.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the firm posted $0.77 EPS. The company’s revenue was up 5.5% on a year-over-year basis. On average, research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.